NCT03129126Phase 2Completed

The Safety, Tolerability and Efficacy of LP-10 in Subjects With Refractory Moderate to Severe Hemorrhagic Cystitis

Study sponsor: Lipella Pharmaceuticals, Inc.

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2023-08-21Actual
Enrollment · participants13Actual
Source updated2023-12-11Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview